Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

58.54
-0.8900-1.50%
Post-market: 58.50-0.0400-0.07%19:55 EDT
Volume:7.91M
Turnover:465.22M
Market Cap:119.17B
PE:16.92
High:59.69
Open:59.61
Low:58.37
Close:59.43
52wk High:62.89
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.38
T/O Rate:0.39%
Dividend:2.49
Dividend Rate:4.25%
EPS(TTM):3.46
EPS(LYR):3.46
ROE:40.44%
ROA:10.29%
PB:6.45
PE(LYR):16.92

Loading ...

Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study

TIPRANKS
·
Mar 18

Bristol-Myers Squibb Is Maintained at Hold by HSBC

Dow Jones
·
Mar 18

Opdualag’s NHS Scotland Debut Adds New Layer To Bristol-Myers Squibb Story

Simply Wall St.
·
Mar 17

Jefferies Adjusts Price Target on Bristol-Myers Squibb to $70 From $68, Maintains Buy Rating

MT Newswires Live
·
Mar 17

Bristol-Myers Squibb Co : Jefferies Raises Target Price to $70 From $68

THOMSON REUTERS
·
Mar 17

U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson

Reuters
·
Mar 17

Covid Vaccine Maker BioNTech Offers Cheap Biotech Play Given Huge Cash Reserves -- Barrons.com

Dow Jones
·
Mar 17

BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis

TIPRANKS
·
Mar 14

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Mar 13

10 dividend stocks investors say can withstand the AI disruption

Bloomberg
·
Mar 13

FDA Approves Bristol-Myers Squibb's TYK2 Inhibitor Deucravacitinib for Active Psoriatic Arthritis

Stock News
·
Mar 13

Century Therapeutics 2025 net loss narrows beating estimates

Reuters
·
Mar 12

BioNTech SE publishes 2025 annual report

Reuters
·
Mar 11

Germany's BioNTech 2025 revenue beats expectations, helped by Bristol Myers Squibb collaboration

Reuters
·
Mar 10

BioNTech Q4 2025 net loss hits EUR 305 million as revenue falls 24% to EUR 907.4 million

Reuters
·
Mar 10

Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating

TIPRANKS
·
Mar 09

Bristol Myers Squibb Says Blood-Cancer Treatment Performed Well in Late-Stage Trial

Dow Jones
·
Mar 09

BRIEF-Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma

Reuters
·
Mar 09

Bristol's cancer treatment meets main goal in late-stage trial

Reuters
·
Mar 09

Bristol-Myers Squibb Co - Mezikd Demonstrates Significant Improvement in Progression-Free Survival in Rrmm

THOMSON REUTERS
·
Mar 09